Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of COS-7 cells, using Stathmin 1 (Phospho-Ser15) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human thymus gland tissue using Stathmin 1 (Phospho-Ser15) antibody. Western blot analysis of extracts from 293 cells, using Stathmin 1 (Phospho-Ser15) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from MDA-MB-231 cells, untreated or treated with TNF-alpha (20ng/ml, 10min) using NF-kappaB p65 (Ab-529) antibody (Line 1 and 2) and NF-kappaB p65 (phospho-Ser529) antibody (Line 3 and 4).)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-kappaB p65 (phospho-Ser529) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human brain tissue using PDGF Receptor beta (phospho-Tyr751) antibody.P-peptide: -(left) +(right))
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of A549 cells, using Moesin/Ezrin/Radixin (Phospho-Thr558) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human pancreas tissue using Moesin/Ezrin/Radixin (Phospho-Thr558) antibody. Western blot analysis of extracts NIH/3T3 Jurkat cells, using Moesin/Ezrin/Radixin (Phospho-Thr558) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody againstnon-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from NIH/3T3 cells, using KOR-1 (Phospho-Ser369) Antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from 293 cells, treated with heat shock, using PR (Phospho-Ser400) antibody. Immunofluorescence analysis of A549 cells, using PR (Phospho-Ser400) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Adrenergic Receptor B2 (Phospho-Ser355+Ser356) antibody. Western blot analysis of extracts from HUVEC cells and COS cells treated with serum (20%, 15mins), using Adrenergic Receptor B2 (Phospho-Ser355+Ser356) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemical analysis of p73 (pY99) staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of p73 (pY99) expression in Jurkat (A), HeLa UV-treated (B) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of FOXO4 (pS197) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of FOXO4 (pS197) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of FOXO4 (pS197) expression in HeLa (A), MM142 (B), HuT78 (C), HEK293T (D), NIH3T3 (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IRS1 (pS307) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IRS1 (pS307) expression in HEK293T insulin-treated (A) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Artemis (pS516) staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Artemis (Phospho-S516) expression in Hela (A), H446 (B), H1688 (C), mouse lung (D) whole cell lysates. (Predicted band size: 78 kD; Observed band size: 78 kD))
IF (Immunofluorescence) (Immunofluorescent analysis of CDK1/2/3 (pT14) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
WB (Western Blot) (Western blot analysis of CDK1/2/3 (pT14) expression in HT29 hydroxyurea-treated (A), HeLa (B), NIH3T3 (C), A431 (D) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of CDC25A (pS75) staining in human tonsil formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of CDC25A (pS75) expression in HEK293T UV-treated (A), Jurkat UV-treated (B), NIH3T3 (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of Histone Deacetylase 5 (pS498) staining in Raw264.7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Histone Deacetylase 5 (pS498) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Histone Deacetylase 5 (pS498) expression in HEK293T LPS-treated (A), Raw264.7 TNFa-treated (B), rat kidney (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of ABL1/2 (pY393/439) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of ABL1/2 (pY393/439) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of ABL1/2 (pY393/439) expression in HeLa colchicine-treated (A), SP2/0 colchicine-treated (B), H9C2 colchicine-treated (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IRS1 (pS1101) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IRS1 (pS1101) expression in HepG2 insulin-treated (A) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using CK-1 gamma 1/2/3 (Phospho-Tyr263) antibody. CK-1 gamma 1/2/3 (Phospho-Tyr263) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Hela cells treated with Forskolin (40nM, 30mins), using Synaptotagmin (phospho-Thr202) antibody.)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Synaptotagmin (phospho-Thr202) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from cos-7cells using Cortactin (phospho-Tyr466) antibody (Line 1 and 2).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Cortactin (phospho-Tyr466) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from K562 cells, treated with EGF (40nM, 30mins), using eNOS (Phospho-Ser615) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKK alpha (pT23) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKK alpha (pT23) expression in HeLa TNFa-treated (A), Raw264.7 TNFa-treated (B), PC12 LPS-treated (C) whole cell lysates.)
WB (Western Blot) (Detection of human Phospho RPA32 (S4/S8) by western blot. Samples: Whole cell lysate (50 ug) from BeWo and AlphaTC1 Clone 9 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) antibody (AAA210838 lot 9) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.)
IP (Immunoprecipitation) (Detection of human Phospho RPA32 (S4/S8) by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells treated with or without etoposide. Antibodies: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) antibody (AAA210838 lot 9) used for IP at 6 ug per reaction followed by treatment with Lambda phosphatase (+) or mock treated (-). For blotting immunoprecipitated Phospho RPA32 (S4/S8), AAA210838 was used at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 75 seconds. Lower Panel: Rabbit anti-RPA32 antibody .)
IHC (Immunohistochemisry) (Detection of mouse Phospho RPA32 (S4/S8) by immunohistochemistry. Sample: FFPE section of mouse gut, MOCK treatment (left) and CIP treatment (right). Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) ((AAA210838 lot 9)) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB)
IHC (Immunohiostchemistry) (Detection of human Phospho RPA32 (S4/S8) by immunohistochemistry. Sample: FFPE section of human breast carcinoma, MOCK treatment (left) and CIP treatment (right). Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) ((AAA210838 lot 9)) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB)
ICC (Immunocytochemistry) (Detection of human Phospho RPA32 (S4/S8) by immunocytochemistry. Samples: Formaldehyde-fixed asynchronous HeLa cells. Untreated cells (left) and etoposide-treated cells (right). Antibody: Affinity purified rabbit anti-Phospho RPA32 (S4/S8) (Cat. No. AAA210838 lot 4) used at a dilution of 1:1,000 (1ug/ml). Detection: Red-fluorescent goat anti-rabbit IgG-heavy and light chain cross-adsorbed Antibody DyLight 594 Conjugated used at a dilution of 1:100. Counterstain: Alexa Fluor 488 phalloidin (green).)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using TOP2A (Phospho-Ser1106) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells, treated with paclitaxel (1uM, 24hours), using TOP2A (Phospho-Ser1106) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with EGF or calf intestinal phosphatase (CIP), using HER2 (Phospho-Tyr1221/Tyr1222) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF cells using HER2(Phospho-Tyr1221/Tyr1222) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from MDA cells untreated or treated with EGF using HER2(Phospho-Tyr1221/Tyr1222) Antibody.)
ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Reactivity
Human
Applications
Immunofluorescence, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF cells using VEGFR2(Phospho-Tyr1214) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using VEGFR2(Phospho-Tyr1214) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from SKOV3 cells using VEGFR2(Phospho-Tyr1214) Antibody(Lane 1) and the same antibody preincubated with blocking peptide(Lane2).)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HT29 cells, treated with serum or calf intestinal phosphatase (CIP), using p53 (Phospho-Ser33) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using p53(Phospho-Ser33) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from HT29 cells using p53(Phospho-Ser33) Antibody and the same antibody preincubated with blocking peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with UV+serum or calf intestinal phosphatase (CIP), using p53 (Phospho-Ser46) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using p53(Phospho-Ser46) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from MCF cells untreated or treated with Anisomycin using p53(Phospho-Ser46) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using FKHR(Phospho-Ser319) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using FKHR(Phospho-Ser319) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells untreated or treated with serum starvation using FKHR(Phospho-Ser319) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF7 cells using AFX(Phospho-Ser197) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using AFX(Phospho-Ser197) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with serum using AFX(Phospho-Ser197) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using PAK1(Phospho-Thr212) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PAK1(Phospho-Thr212) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with forskolin using PAK1(Phospho-Thr212) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human brain tissue using MAP2K3 (Phospho-Thr222) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells treated with serum using MAP2K3 (Phospho-Thr222) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human brain tissue using STK39 (Phospho-Ser309) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from COLO cells using STK39 (Phospho-Ser309) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with Anisomycin or calf intestinal phosphatase (CIP), using JNK1/JNK2/JNK3 (phospho-Thr183/Tyr185) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using JNK1/JNK2/JNK3(phospho-Thr183/Tyr185) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from C6 cells untreated or treated with anisomycin using JNK1/JNK2/JNK3(phospho-Thr183/Tyr185) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using c-Cbl(phospho-Tyr700) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Cbl(Phospho-Tyr700) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HT29 cells untreated or treated with UV using c-Cbl(phospho-Tyr700) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with Anisomycin or calf intestinal phosphatase (CIP), using HSP27 (Phospho-Ser15) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells showing cytoplasmic staining using HSP27(Phospho-Ser15) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HSP27(Phospho-Ser15) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with UV using HSP27(Phospho-Ser15) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreatedor treated with TNF-alpha using NFkappaB-p65 (Phospho-Ser529)Antibody.)
WB (Western Blot) (Western blot analysis of extracts from MCF cells, treated with TNFa+CA or calf intestinal phosphatase (CIP), using NFkappaB-p65 (Phospho-Ser529) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using NFkB-p65(Phospho-Ser529) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFkB-p65(Phospho-Ser529) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using JunB(Phospho-Ser79) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using JunB(Phospho-Ser79) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT5A(Phospho-Ser780) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from K562 cells untreated or treated with IL-4 using STAT5A(Phospho-Ser780) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Estrogen Receptor-a(Phospho-Ser104) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MCF-7 cells untreated or treated with E2 and EGF using Estrogen Receptor-a(Phospho-Ser104) Antibody)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Paxillin(Phospho-Tyr118) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells untreated or treated with serum using Paxillin(Phospho-Tyr118) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Androgen Receptor(Phospho-Ser213) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from DU145 cells using Androgen Receptor(Phospho-Ser213) Antibody(Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFkB-p65(Phospho-Thr505) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HL60 cells untreated or treated with TNF-a using NFkB-p65(Phospho-Thr505) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.